Effects of Atorvastatin on Systemic and Renal Nitric Oxide in Healthy Man

REFERENCES

• Istvan ES, Deisenhofer J. Structural mechanism for statin inhibition of HMG-CoA reductase. Science 2001; 292(5519): 1160–1164.
   PubMed Web of Science ®Google Scholar
• Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial. Lancet 2002; 360(9326):7–22.
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, . Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376(9753):1670–1681.
   PubMed Web of Science ®Google Scholar
• Brugts JJ, Yetgin T, Hoeks SE, . The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009; 338:b2376.
   PubMed Web of Science ®Google Scholar
• Sacks FM, Pfeffer MA, Moye LA, . The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996; 335(14):1001–1009.
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Kjekshus J, Berg K, . Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). 1994. Atheroscler Suppl 2004; 5(3):81–87.
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH, . Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004; 350(15):1495–1504.
   PubMed Web of Science ®Google Scholar
• Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008; 14(1):37–44.
   PubMed Web of Science ®Google Scholar
• Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol 2005; 16(6):624–629.
   PubMed Web of Science ®Google Scholar
• Athyros VG, Mikhailidis DP, Papageorgiou AA, . The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. J Clin Pathol 2004; 57(7):728–734.
   PubMed Web of Science ®Google Scholar
• Tonelli M, Moye L, Sacks FM, Cole T, Curhan GC. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. J Am Soc Nephrol 2003; 14(6):1605–1613.
   PubMed Web of Science ®Google Scholar
• Lecian D, Demova H, Lodererova A, . Renal effects of HMG-CoA reductase inhibition in a rat model of chronic inhibition of nitric oxide synthesis. Kidney Blood Press Res 2006; 29(3):135–143.
   PubMed Web of Science ®Google Scholar
• Atthobari J, Brantsma AH, Gansevoort RT, . The effect of statins on urinary albumin excretion and glomerular filtration rate: results from both a randomized clinical trial and an observational cohort study. Nephrol Dial Transplant 2006; 21(11):3106–3114.
   PubMed Web of Science ®Google Scholar
• Paulsen L, Holm C, Bech JN, Starklint J, Pedersen EB. Effects of statins on renal sodium and water handling: acute and short-term effects of atorvastatin on renal haemodynamics, tubular function, vasoactive hormones, blood pressure and pulse rate in healthy, normocholesterolemic humans. Nephrol Dial Transplant 2008; 23(5):1556–1561.
   PubMedGoogle Scholar
• Christensen FH, Hansen T, Stankevicius E, Buus NH, Simonsen U. Elevated pressure selectively blunts flow-evoked vasodilatation in rat mesenteric small arteries. Br J Pharmacol 2007; 150(1):80–87.
   PubMed Web of Science ®Google Scholar
• Kurtz A, Wagner C. Role of nitric oxide in the control of renin secretion. Am J Physiol 1998; 275(6 Pt 2):F849–F862.
   PubMed Web of Science ®Google Scholar
• Ortiz PA, Garvin JL. Role of nitric oxide in the regulation of nephron transport. Am J Physiol Renal Physiol 2002; 282(5):F777–F784.
   PubMed Web of Science ®Google Scholar
• Bech JN, Nielsen CB, Pedersen EB. Effects of systemic NO synthesis inhibition on RPF, GFR, UNa, and vasoactive hormones in healthy humans. Am J Physiol 1996; 270(5 Pt 2):F845–F851.
   PubMed Web of Science ®Google Scholar
• Larsen T, Mose FH, Bech JN, Pedersen EB. Effect of nitric oxide inhibition on blood pressure and renal sodium handling. A dose-response study in healthy man. Clin Exp Hypertens 2012. doi:10.3109/10641963.2012.681727
   Google Scholar
• John S, Delles C, Jacobi J, . Rapid improvement of nitric oxide bioavailability after lipid-lowering therapy with cerivastatin within two weeks. J Am Coll Cardiol 2001; 37(5):1351–1358.
   PubMed Web of Science ®Google Scholar
• Ott C, Schlaich MP, Schmidt BM, Titze SI, Schaufele T, Schmieder RE. Rosuvastatin improves basal nitric oxide activity of the renal vasculature in patients with hypercholesterolemia. Atherosclerosis 2008; 196(2):704–711.
   PubMed Web of Science ®Google Scholar
• Omori H, Nagashima H, Tsurumi Y, . Direct in vivo evidence of a vascular statin: a single dose of cerivastatin rapidly increases vascular endothelial responsiveness in healthy normocholesterolaemic subjects. Br J Clin Pharmacol 2002; 54(4):395–399.
   PubMed Web of Science ®Google Scholar
• John S, Schneider MP, Delles C, Jacobi J, Schmieder RE. Lipid-independent effects of statins on endothelial function and bioavailability of nitric oxide in hypercholesterolemic patients. Am Heart J 2005; 149(3):473.
   PubMedGoogle Scholar
• Landmesser U, Bahlmann F, Mueller M, . Simvastatin versus ezetimibe: pleiotropic and lipid-lowering effects on endothelial function in humans. Circulation 2005; 111(18):2356–2363.
   PubMed Web of Science ®Google Scholar
• O’Driscoll G, Green D, Taylor RR. Simvastatin, an HMG-coenzyme a reductase inhibitor, improves endothelial function within 1 month. Circulation 1997; 95(5):1126–1131.
   PubMed Web of Science ®Google Scholar
• Chen H, Ren JY, Xing Y, . Short-term withdrawal of simvastatin induces endothelial dysfunction in patients with coronary artery disease: a dose-response effect dependent on endothelial nitric oxide synthase. Int J Cardiol 2009; 131(3): 313–320.
   PubMed Web of Science ®Google Scholar
• Ludolph B, Bloch W, Kelm M, Schulz R, Kleinbongard P. Short-term effect of the HMG-CoA reductase inhibitor rosuvastatin on erythrocyte nitric oxide synthase activity. Vasc Health Risk Manag 2007; 3(6):1069–1073.
   PubMedGoogle Scholar
• Energy and protein requirements. Report of a joint FAO/WHO/UNU Expert Consultation. World Health Organ Tech Rep Ser 1985; 724:1–206.
   PubMedGoogle Scholar
• Matthesen SK, Larsen T, Vase H, Lauridsen TG, Pedersen EB. Effect of potassium supplementation on renal tubular function, ambulatory blood pressure and pulse wave velocity in healthy humans. Scand J Clin Lab Invest 2011; 72(1):78–86.
   PubMed Web of Science ®Google Scholar
• Pedersen RS, Bentzen H, Bech JN, Pedersen EB. Effect of water deprivation and hypertonic saline infusion on urinary AQP2 excretion in healthy humans. Am J Physiol Renal Physiol 2001; 280(5):F860–F867.
   PubMed Web of Science ®Google Scholar
• Hager H, Kwon TH, Vinnikova AK, . Immunocytochemical and immunoelectron microscopic localization of alpha-, beta-, and gamma-ENaC in rat kidney. Am J Physiol Renal Physiol 2001; 280(6):F1093–F1106.
   PubMed Web of Science ®Google Scholar
• Melikian N, Seddon MD, Casadei B, Chowienczyk PJ, Shah AM. Neuronal nitric oxide synthase and human vascular regulation. Trends Cardiovasc Med 2009; 19(8):256–262.
   PubMed Web of Science ®Google Scholar
• Mount PF, Power DA. Nitric oxide in the kidney: functions and regulation of synthesis. Acta Physiol (Oxf) 2006; 187(4):433–446.
   PubMed Web of Science ®Google Scholar
• Antoniades C, Bakogiannis C, Leeson P, . Rapid, direct effects of statin treatment on arterial redox state and nitric oxide bioavailability in human atherosclerosis via tetrahydrobiopterin-mediated endothelial nitric oxide synthase coupling. Circulation 2011; 124(3):335–345.
   PubMed Web of Science ®Google Scholar
• Datar R, Kaesemeyer WH, Chandra S, Fulton DJ, Caldwell RW. Acute activation of eNOS by statins involves scavenger receptor-B1, G protein subunit Gi, phospholipase C and calcium influx. Br J Pharmacol 2010; 160(7):1765–1772.
   PubMed Web of Science ®Google Scholar
• Mattson DL. Importance of the renal medullary circulation in the control of sodium excretion and blood pressure. Am J Physiol Regul Integr Comp Physiol 2003; 284(1):R13–R27.
   PubMed Web of Science ®Google Scholar
• Lockhart JC, Larson TS, Knox FG. Perfusion pressure and volume status determine the microvascular response of the rat kidney to NG-monomethyl-L-arginine. Circ Res 1994; 75(5):829–835.
   PubMed Web of Science ®Google Scholar
• Damkjaer M, Vafaee M, Moller ML, . Renal cortical and medullary blood flow responses to altered NO availability in humans. Am J Physiol Regul Integr Comp Physiol 2010; 299(6):R1449–R1455.
   PubMed Web of Science ®Google Scholar
• Bech JN, Nielsen EH, Pedersen RS, Svendsen KB, Pedersen EB. Enhanced sodium retention after acute nitric oxide blockade in mildly sodium loaded patients with essential hypertension. Am J Hypertens 2007; 20(3):287–295.
   PubMed Web of Science ®Google Scholar
• Ott C, Ritt M, Titze SI, Schaufele T, Schmieder RE. Rosuvastatin does not affect intrarenal hemodynamics in patients with hypercholesterolemia. J Nephrol 2009; 22(5):675–681.
   PubMed Web of Science ®Google Scholar
• Lauridsen TG, Vase H, Starklint J, . Increased renal sodium absorption by inhibition of prostaglandin synthesis during fasting in healthy man. A possible role of the epithelial sodium channels. BMC Nephrol 2010; 11:28.
   PubMedGoogle Scholar
• Garvin JL, Ortiz PA. The role of reactive oxygen species in the regulation of tubular function. Acta Physiol Scand 2003; 179(3):225–232.
   PubMedGoogle Scholar
• Wassmann S, Laufs U, Muller K, . Cellular antioxidant effects of atorvastatin in vitro and in vivo. Arterioscler Thromb Vasc Biol 2002; 22(2):300–305.
   PubMed Web of Science ®Google Scholar
• Wagner AH, Kohler T, Ruckschloss U, Just I, Hecker M. Improvement of nitric oxide-dependent vasodilatation by HMG-CoA reductase inhibitors through attenuation of endothelial superoxide anion formation. Arterioscler Thromb Vasc Biol 2000; 20(1):61–69.
   PubMed Web of Science ®Google Scholar
• Briones AM, Rodriguez-Criado N, Hernanz R, . Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension 2009; 54(1):142–149.
   PubMed Web of Science ®Google Scholar